A randomized, comparative, multicentric evaluation of atenolol/amlodipine combination with atenolol alone in essential hypertensive patients

American Journal of Therapeutics

Volumn 17, Issue 1, 2010, Pages 46-52

  Pareek, Anil ^a   Salkar, Harsha ^b   Mulay, Pradeep ^c   Desai, Shubha ^d   Chandurkar, Nitin ^a   Redkar, Neelam ^e  

^a Ipca Laboratories Ltd   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

^c GOVERNMENT MEDICAL COLLEGE   (India)

^d SMT NHL MUNICIPAL MEDICAL COLLEGE   (India)

^e LOKMANYA TILAK MUNICIPAL GENERAL HOSPITAL   (India)

Author keywords

blocker; Amlodipine; Atenolol; Calcium antagonist; Hypertension

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATENOLOL; ATENOLOL; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; GASTRITIS; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 76149122546     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181a9db74     Document Type: Article

References (14)

1. He J, Welton PK. Epidemiology and prevention of hypertension. Med Clin North Am. 1997;81:1077-1097.
2. Whelton PK. Epidemiology of hypertension. Lancet. 1994; 344:101-106.
3. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-1360.
4. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
5. Carretero OA, Oparil S. Essential hypertension part I: definition and etiology. Circulation. 2000;101:329-335. (Pubitemid 30054162)
6. White WB, Murwin D, Chrysant SG, et al. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Pressure Monit. 2008;13:21-27.
7. Scholze J, Bida M, Hansen A, et al. Initiation of hypertension treatment with a fixed-dose combination or its monocomponents-does it really matter? Int J Clin Pract. 2006;60:265-274.
8. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, the JNC 7 report. JAMA. 2003;289:2560-2572.
9. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-Eureopean Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1153.
10. Zidek W. Hachdruckleitlinien iiberabeitet. Was ist Praxisrelevant? MMW Fortschr Med. 2004;1-2:16/37-8/17.
11. Maclean D, Mitchell ET, Irvine RL, et al. Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension. Br J Clin Pharmacol. 1990;29:455-463.
12. Saito I, Saruta T, ADVANCE-combi study group. Controlled release of nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study. Hypertens Res. 2006;29: 789-796.
13. The Canadian Enalpril Study Group. Comparison of monotherapy with enalpril and atenolol in mild to moderate hypertension. CMAJ. 1987;37:803-808.
14. Ling G, Liu A, Shen F, et al. Effects of combination therapy with atenolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats. Acta Pharmacol Sin. 2007;28: 1755-1760.